Gilotrif (afatinib) for the Treatment of Metastatic Non-Small cell Lung Cancer

Boehringer Ingelheim headquartered at Ingelheim, Germany, developed the metastatic non-small cell lung cancer drug, Gilotrif. Image: courtesy of Boehringer Ingelheim.